Abstract
Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.
| Original language | English |
|---|---|
| Pages (from-to) | 163-167 |
| Number of pages | 5 |
| Journal | Journal of Glaucoma |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2004 |
Fingerprint
Keywords
- Brimonidine
- Drug toxicity
- Glaucoma
ASJC Scopus subject areas
- Ophthalmology
Cite this
Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy. / Manni, Gianluca; Centofanti, Marco; Sacchetti, Marta; Oddone, Francesco; Bonini, Stefano; Parravano, Mariacristina; Bucci, Massimo Gilberto.
In: Journal of Glaucoma, Vol. 13, No. 2, 04.2004, p. 163-167.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy
AU - Manni, Gianluca
AU - Centofanti, Marco
AU - Sacchetti, Marta
AU - Oddone, Francesco
AU - Bonini, Stefano
AU - Parravano, Mariacristina
AU - Bucci, Massimo Gilberto
PY - 2004/4
Y1 - 2004/4
N2 - Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.
AB - Purpose: To identify demographic and clinical characteristics associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. Patients and Methods: In this retrospective study, 133 patients affected by primary open-angle, pigmentary, narrow angle, or pseudo-exfoliative glaucoma and treated with brimonidine tartrate 0.2% were divided into two groups: allergic and non allergic to brimonidine tartrate 0.2%. The distribution of demographic (age and sex), local (history of allergic conjunctivitis, previous eye-drop ocular allergy, use of other concurrent topical medications, amount of topical medications previously used, use of contact lenses, and tear film production), and systemic (history of systemic allergies and use of systemic drugs) factors was evaluated by comparing the brimonidine tartrate 0.2% allergic and the non-allergic groups. Results: In this study, 13.5% of patients (18 of 133) developed brimonidine ocular allergy generally within two weeks from the beginning of treatment (mean time 14.8 ± 17.9 days). The brimonidine tartrate 0.2% allergic group showed a significantly higher frequency of history of ocular allergy to eye-drops (P = 0.048) and to topical beta-blockers (P = 0.019) when compared with the brimonidine tartrate 0.2% non-allergic group. Moreover, the allergic group showed a decreased tear film production (P = 0.044). Conclusion: This study showed that history of eye-drop allergies and reduction of tear film production were more frequently associated with the development of brimonidine tartrate 0.2%-induced ocular allergy.
KW - Brimonidine
KW - Drug toxicity
KW - Glaucoma
UR - http://www.scopus.com/inward/record.url?scp=1642399896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642399896&partnerID=8YFLogxK
U2 - 10.1097/00061198-200404000-00014
DO - 10.1097/00061198-200404000-00014
M3 - Article
C2 - 15097264
AN - SCOPUS:1642399896
VL - 13
SP - 163
EP - 167
JO - Journal of Glaucoma
JF - Journal of Glaucoma
SN - 1057-0829
IS - 2
ER -